Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cat eye syndrome chromosome region, candidate 7 (CECR7, also known as SAHL1) is a human long non-coding RNA (lncRNA) gene located on chromosome 22. Unlike typical therapeutic targets such as receptors, enzymes, or ion channels, CECR7 is a non-protein-coding RNA and thus not a classical drug target. It is associated with cat eye syndrome and has been linked to hepatocellular carcinoma in gene-disease association databases, but there is no evidence that it interacts with drugs or serves as a biomarker or direct therapeutic target. The gene's precise molecular function is unclear, and it is categorized mainly as a genomic locus of interest rather than as a validated protein or druggable target[1][2][3][4][5][6][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cat eye syndrome chromosome region, candidate 7 (non-protein coding) (CECR7).